---
title: "12 Health Care Stocks Moving In Friday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304692952.md"
description: "Several healthcare stocks moved in Friday's after-market session, largely driven by Q3 earnings reports. Gainers included Karyopharm Therapeutics (+17.5%), Nkarta (+8.67%), and Polyrizon (+7.85%). Conversely, losers featured Enliven Therapeutics (-5.5%), Virax Biolabs Group (-5.3%), and BeOne Medicines (-4.85%). Market caps ranged from $1.2 million to $43.8 billion."
datetime: "2026-11-06T21:05:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304692952.md)
  - [en](https://longbridge.com/en/news/304692952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304692952.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's After-Market Session

### Gainers

-   **Karyopharm Therapeutics** (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million.
-   **Nkarta** (NASDAQ:NKTX) stock increased by 8.67% to $1.88. The company's market cap stands at $112.4 million. As per the news, the Q3 earnings report came out yesterday.
-   **Polyrizon** (NASDAQ:PLRZ) stock rose 7.85% to $12.5. The company's market cap stands at $28.1 million.
-   **SAB Biotherapeutics** (NASDAQ:SABS) shares rose 5.28% to $3.19. The market value of their outstanding shares is at $267.4 million. As per the news, the Q3 earnings report came out yesterday.
-   **Faeth Therapeutics** (NASDAQ:FTH) shares moved upwards by 3.99% to $22.93. The market value of their outstanding shares is at $513.5 million. The company's, Q3 earnings came out 3 days ago.
-   **Neumora Therapeutics** (NASDAQ:NMRA) stock rose 3.31% to $0.52. The market value of their outstanding shares is at $91.5 million.

### Losers

-   **Enliven Therapeutics** (NASDAQ:ELVN) shares decreased by 5.5% to $46.74 during Friday's after-market session. The company's market cap stands at $3.1 billion. As per the news, the Q3 earnings report came out yesterday.
-   **Virax Biolabs Group** (NASDAQ:VRAX) shares decreased by 5.3% to $0.75.
-   **BeOne Medicines** (NASDAQ:ONC) shares fell 4.85% to $387.25. The market value of their outstanding shares is at $43.8 billion. As per the press release, Q3 earnings came out yesterday.
-   **National Healthcare** (AMEX:NHC) shares decreased by 4.66% to $198.5. The market value of their outstanding shares is at $3.2 billion. The company's, Q3 earnings came out today.
-   **Lakewood-Amedex** (NASDAQ:LABT) shares declined by 3.97% to $0.37. The company's market cap stands at $1.2 million.
-   **Jaguar Health** (NASDAQ:JAGX) shares fell 3.52% to $0.39. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [NKTX.US](https://longbridge.com/en/quote/NKTX.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [PLRZ.US](https://longbridge.com/en/quote/PLRZ.US.md)
- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)
- [KPTIQ.US](https://longbridge.com/en/quote/KPTIQ.US.md)
- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)
- [JAGX.US](https://longbridge.com/en/quote/JAGX.US.md)
- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)
- [NMRA.US](https://longbridge.com/en/quote/NMRA.US.md)
- [SABS.US](https://longbridge.com/en/quote/SABS.US.md)

## Related News & Research

- [Virax Biolabs Presents Plans for 2027 U.S. Diagnostic Testing Launch](https://longbridge.com/en/news/305974687.md)
- [ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout](https://longbridge.com/en/news/305860981.md)
- [BeOne commits $3M to expand CLL Society patient education pact](https://longbridge.com/en/news/305853990.md)
- [FDA accepts Karyopharm's Xpovio combination application for myelofibrosis review](https://longbridge.com/en/news/305821921.md)
- [Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications](https://longbridge.com/en/news/305191506.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**